tirzepatide 16.7 MG/ML Injectable Solution

RxCUI: 2732442
RxNorm name: tirzepatide 16.7 MG/ML Injectable Solution
Display name: tirzepatide 16.7 MG/ML Injectable Solution
Full name: tirzepatide 16.7 MG/ML Injectable Solution
Term type: PSN
Status: DailyMed mapping
Updated: 2026-06-04 23:39:22

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Mounjaro	TIRZEPATIDE	Eli Lilly and Company	d2d7da5d-ad07-4228-955f-cf7e355c8cc0	2026-04-22	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 2732442
Zepbound	TIRZEPATIDE	Eli Lilly and Company	487cd7e7-434c-4925-99fa-aa80b1cc776b	2026-04-22	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 2732442

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 2 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
487cd7e7-434c-4925-99fa-aa80b1cc776b	tirzepatide 16.7 MG/ML Injectable Solution [PSN] · tirzepatide 16.7 MG/ML Injectable Solution [SCD]	2	38	These highlights do not include all the information needed to use ZEPBOUND safely and effectively. See full prescribing information for ZEPBOUND. ZEPBOUND ® (tirzepatide) Injection, for subcutaneous use Initial U.S. Approval: 2022	20260422
d2d7da5d-ad07-4228-955f-cf7e355c8cc0	tirzepatide 16.7 MG/ML Injectable Solution [PSN] · tirzepatide 16.7 MG/ML Injectable Solution [SCD]	2	38	These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO ® (tirzepatide) Injection, for subcutaneous use Initial U.S. Approval: 2022	20260422